Indies Pharma Jamaica Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Guna Muppuri

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	3.9yrs

Recent management updates

Recent updates

CEO

Guna Muppuri

no data

Tenure

Dr. Guna Sekhar Muppuri is Founder of Indies Pharma Jamaica Limited and serves as it's Executive Chairman, President and Chief Executive Officer. He is a Medical Doctor by profession and the Founder of th...

Board Members

Name	Position	Tenure	Compensation	Ownership
Guna Muppuri	Founder	no data	no data	no data
Vishnu Muppuri	Co-Founder	no data	no data	1.74% JMD 64.6m
Lissant Mitchell	Non-Executive Independent Director	3.9yrs	no data	0.015% JMD 558.0k
Kevin Donaldson	Non Executive Independent Director	3.9yrs	no data	0.050% JMD 1.8m
Trevor McCartney	Non-Executive Independent Director	no data	no data	0.015% JMD 558.0k
Dev Singh	Non-Executive Independent Director	5.3yrs	no data	no data

3.9yrs

Average Tenure

Experienced Board: INDIES's board of directors are considered experienced (3.9 years average tenure).

Indies Pharma Jamaica Management

Management criteria checks 1/4

Key information

Recent management updates

Indies Pharma Jamaica Limited, Annual General Meeting, May 29, 2024

Insufficient new directors

Indies Pharma Jamaica Limited Announces Appointment of Directors

Recent updates

Investor sentiment improves as stock rises 21%

Second quarter 2024 earnings released: EPS: JA$0.053 (vs JA$0.02 in 2Q 2023)

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Indies Pharma Jamaica Limited, Annual General Meeting, May 29, 2024

First quarter 2024 earnings released: EPS: JA$0.047 (vs JA$0.044 in 1Q 2023)

Full year 2023 earnings released: EPS: JA$0.16 (vs JA$0.17 in FY 2022)

Full year 2023 earnings released: EPS: JA$0.16 (vs JA$0.17 in FY 2022)

Investor sentiment deteriorates as stock falls 16%

Insufficient new directors

Third quarter 2023 earnings released: EPS: JA$0.06 (vs JA$0.05 in 3Q 2022)

Second quarter 2023 earnings released: EPS: JA$0.02 (vs JA$0.05 in 2Q 2022)

Investor sentiment improves as stock rises 19%

Upcoming dividend of JA$11.33 per share at 3.4% yield

Investor sentiment improves as stock rises 26%

First quarter 2023 earnings released: EPS: JA$0.04 (vs JA$0.04 in 1Q 2022)

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorates as stock falls 22%

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: JA$0.05 (vs JA$0.03 in 3Q 2021)

Second quarter 2022 earnings released: EPS: JA$0.05 (vs JA$0.01 in 2Q 2021)

Upcoming dividend of JA$0.11 per share

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS JA$0.01 (vs JA$0.04 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS JA$0.02 (vs JA$0.05 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS JA$0.04 (vs JA$0.03 in 1Q 2020)

Upcoming Dividend of JA$0.11 Per Share

New 90-day high: JA$2.89

Full year 2020 earnings released: EPS JA$0.15 (vs JA$0.12 in FY 2019)

Investor sentiment improved over the past week

New 90-day low: JA$2.31

Full year 2020 earnings released: EPS JA$0.15

New 90-day low: JA$2.43

Indies Pharma Jamaica Limited Announces Appointment of Directors

Third quarter earnings released

CEO

Tenure

Board Members

Average Tenure